Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status:
Completed
Trial end date:
2018-02-07
Target enrollment:
Participant gender:
Summary
The study investigates the effect of 4 weeks of twice daily treatment of four different doses
of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to
severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to
one of the five treatment options.